From biosimilars scale to targeted oncology innovation, recent deals highlight how companies are using acquisition to accelerate positioning across key therapeutic and market opportunities.

Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.

We've had Eyes on the evolving Pharma Pipeline Strategy. This week we highlight how many companies are leaning on external innovation with full acquisition s to targeted asset deals to drive long-term strategy.

We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?